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An empirical comparison of the St George’s
Respiratory Questionnaire (SGRQ) and the
Chronic Respiratory Disease Questionnaire
(CRQ) in a clinical trial setting
Maureen Rutten-van Mölken, Bianca Roos, J A Van Noord
Abstract
Background—The Chronic Respiratory
Questionnaire (CRQ) and the St George’s
Respiratory Questionnaire (SGRQ) are
the two most widely used quality of life
questionnaires in chronic obstructive pul-
monary disease (COPD). A study was
undertaken to compare directly the self-
administered version of the CRQ and the
SGRQ with respect to feasibility, internal
consistency, validity, and sensitivity to
changes resulting from bronchodilator
therapy.
Methods—One hundred and forty four
patients with moderate or severe COPD
were randomly assigned to receive three
months of treatment with either salm-
eterol, salmeterol + ipratropium bromide,
or placebo. Quality of life was measured at
baseline and after 12 weeks of treatment.
Results—The proportions of missing
values per patient were low for both ques-
tionnaires (0.54% for the CRQ and 2% for
the SGRQ). The internal consistency was
good for both questionnaires (Cronbach’s
á coeYcients>0.84 for the CRQ and>0.76
for the SGRQ). Factor analysis confirmed
the original domain structure of the CRQ
but not of the SGRQ. Correlations with
forced expiratory volume in one second
(FEV1) % predicted and peak expiratory
flow rate (PEFR) were low for both
questionnaires but better for the SGRQ
than for the CRQ. The ability to discrimi-
nate between subjects with diVerent levels
of FEV1 was somewhat better for the
SGRQ. The correlations with symptom
scores were comparable for both ques-
tionnaires. Cross sectionally, the scores of
the two questionnaires were moderately to
highly correlated (coeYcients ranged
from 0.35 to 0.72). Longitudinally, these
correlations were lower (coeYcients
ranged from 0.17 to 0.54) but were still
significant. The CRQ total and emotions
score and the SGRQ symptoms score were
the most responsive to change. The SGRQ
symptoms domain was the only domain
where the improvement in patients re-
ceiving combination treatment crossed
the threshold for clinical relevance.
Conclusions—Since this analysis of reli-
ability, validity, and responsiveness to
change did not clearly favour one instru-
ment above the other, the choice between
the CRQ and the SGRQ can be based on
other considerations such as the required
sample size or the availability of reference
values.
(Thorax 1999;54:995–1003)
Keywords: chronic obstructive pulmonary disease;
health status assessment; quality of life; St George’s
Respiratory Questionnaire; Chronic Respiratory Dis-
ease Questionnaire
Over the last decade the potential value of
incorporating disease specific quality of life
questionnaires into clinical trials evaluating
medical interventions for chronic obstructive
pulmonary disease (COPD) has become well
established. Since the associations between
spirometric values and disease specific quality
of life questionnaires have been shown to be
weak, it is generally recognised that these
instruments contribute valid additional infor-
mation about the daily functioning and well
being of patients with COPD. Two disease spe-
cific quality of life questionnaires are widely
used in patients with COPD: the Chronic Res-
piratory Disease Questionnaire (CRQ) devel-
oped by Guyatt et al in 19871 and the St
George’s Respiratory Questionnaire (SGRQ)
developed by Jones et al in 1991.2 3 The SGRQ
is a self-administered questionnaire whereas
the CRQ was developed to be interviewer-
administered (at a later stage a self-
administered version of the CRQ became
available). Both questionnaires have been used
to assess the eVects of interventions such as
drug therapies,3–6 oxygen therapy,7 8 and pul-
monary rehabilitation or training
programmes.9–12
Both questionnaires have already been
shown to be reliable and valid, but there are few
direct comparisons of the two questionnaires in
the same patients. One study compared their
discriminative properties and reported no sub-
stantial diVerences between the two question-
naires in the correlation with physiological
parameters, exercise capacity, dyspnoea, anxi-
ety, and depression.13 Another study using the
interviewer-administered version of the CRQ
in routine clinical practice looked into the
responsiveness of both questionnaires by com-
paring patients who said their health had
changed with patients who said their health
had not changed.14 No diVerences in respon-
siveness between the two questionnaires were
found. To our knowledge there are no papers
comparing the performance of both question-
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naires in a randomised clinical trial assessing
diVerent bronchodilator therapies.
A study was undertaken to compare the
SGRQ and CRQ in terms of feasibility,
reliability, validity, and sensitivity to change
when applied to patients with moderate to
severe COPD who participated in a clinical
trial comparing three diVerent bronchodilator
therapies: (1) salmeterol, (2) salmeterol plus
ipratropium bromide, and (3) placebo. We
used the self-administered version of the CRQ
which has not been validated on a large scale.
This direct comparison was deliberately per-
formed within a clinical trial to enable a com-
parison of the ability to detect change.
Methods
PATIENTS
Patients aged between 40 and 75 years of age
diagnosed with COPD according to the ATS
criteria were included in the study. The
pre-bronchodilator FEV1 had to be between
40% and 65% of predicted normal and the
FEV1/FVC was required to be <60% predicted
after inhalation of 200 µg salbutamol. They
were required to experience symptoms on mild
exertion such as getting dressed or washed on
at least four out of seven days of the run in
period. Current smokers or previous smokers
with a smoking history equivalent to 10 pack
years were included. Previous smokers should
have stopped smoking for at least six months
prior to the run in visit. Patients were excluded
if they required regular oxygen therapy, had a
history of asthma, allergic rhinitis, or other res-
piratory diseases, were atopic, had a serious
concomitant disease, a respiratory tract infec-
tion, or a change in medication within six weeks
of the commencement of the study. All mainte-
nance drugs other than the study medication
were continued at constant dosage throughout
the study.
STUDY DESIGN
The study was conducted in three Dutch out-
patient clinics and had a double blind, double
dummy, parallel group design. Patients were
randomly assigned to one of the following three
groups, each of which received treatment for 12
weeks: (1) 50 µg salmeterol twice daily plus
40 µg ipratropium bromide four times daily;
(2) 50 µg salmeterol twice daily plus placebo
matched to ipratropium bromide; or (3)
placebo matched to ipratropium bromide plus
placebo matched to salmeterol. Randomisation
was stratified by current smoker or ex-smoker.
Patients were given Ventolin metered dose
inhalers or Rotadisks for symptomatic relief.
They were scheduled to visit the clinic at run
in, at the randomisation visit after two weeks of
run in, after four, eight and 12 weeks of
treatment, and two weeks after cessation of the
treatment. Quality of life measurements were
conducted at the end of the run in period and
after 12 weeks of treatment. These measure-
ments were conducted before the lung function
measurements. During the second administra-
tion of the quality of life questionnaires the
patients were shown the answers they had given
at baseline.15 The study was approved by the
medical ethics committees of the three partici-
pating centres.
SYMPTOMS
Daytime symptoms were recorded in the diary
on a six point scale ranging from 0 (no
symptoms at rest or on exertion) to 5 (severe
symptoms at rest, unable to perform any exer-
tion). Night-time symptom scores ranged from
0 (no symptoms during the night) to 4 (symp-
toms so severe that they did not sleep at all).
CLINICAL OUTCOME MEASURES
Pre-bronchodilator FEV1 and peak expiratory
flow rate (PEFR) were assessed at each clinic
visit using the best of three measurements.
Patients were given a diary to record three
PEFR measurements every morning and every
evening. In this diary they also recorded the
number of daytime and night-time puVs of res-
cue medication and their symptom score.
Diary card data for each patient were summa-
rised by calculating means and standard devia-
tions for the two week run in period and the last
four weeks of the treatment period.
HEALTH STATUS MEASURES
St George’s Respiratory Questionnaire (SGRQ)
The SGRQ is designed to measure the impact
of chest disease on health related quality of life
and well being.2 3 It can be used in COPD as
well as in asthma. The responses to its 50 items
can be aggregated into an overall score and
three subscores for symptoms, activity, and
impact. The number of response options per
question varies from two to five. Responses are
weighted and scores are calculated by dividing
the summed weights by the maximum possible
weight and expressing the result as a percent-
age, 0% being the best possible score and
100% the worst. The weights appear to be
similar in diVerent countries and languages.16
The minimally clinically important response to
treatment is defined as an improvement of 4%
on the separate domains and the total score.2
The SGRQ was reported to be valid and
reliable in patients with asthma and
COPD.2 3 17 19
Chronic Respiratory Disease Questionnaire
(CRQ)
The CRQ was the first instrument developed
to measure quality of life of patients with
COPD.1 It cannot be used for asthma. It is
available in an interview version and a
self-administered version. We have used the
self-administered version, with a recall period
of four weeks. The questionnaire contains 20
questions which can be divided into four
domains: dyspnoea (5 questions), fatigue (4
questions), emotional functioning (7 ques-
tions), and mastery (4 questions). The dys-
pnoea domain is “individualised” which means
that it is made up of five activities chosen by a
patient to cause the greatest shortness of
breath. The patient then rates the dyspnoea on
these self-selected activities during subsequent
administrations of the CRQ. Answers can be
scored on a seven point scale ranging from 1
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which indicates maximum impairment to 7
which indicates no impairment. The results are
expressed as the mean score for each domain
and the mean overall score. The minimally
important diVerence was found to be an
improvement (or deterioration) of 0.5.20 21 The
CRQ was reported to be reliable and valid.4 22
The SGRQ was originally developed in Brit-
ish English and the CRQ was originally devel-
oped in Canadian English. We have used exist-
ing standard Dutch versions of the original
questionnaires. The translation procedure to
obtain these Dutch versions included mini-
mally forward-backward translation, discus-
sion of disagreement over wording by bilingual
speakers, and pilot testing in COPD patients.
ANALYSIS
Baseline characteristics
Analysis of diVerences in baseline characteris-
tics between the treatment groups were based
on analysis of variance for continuous data and
Kruskal-Wallis tests for ordinal data. DiVer-
ences in proportions were analysed using ÷2
tests.
Questionnaire content
We performed a qualitative comparison of the
content of the domains of the two question-
naires. If the content of two domains was
judged to refer to the same underlying concept,
they were judged comparable.
Feasibility
A qualitative assessment of the feasibility was
performed by looking at the length of the ques-
tions, the way they are phrased, the diYculty of
and variations in the response options, and the
variations in recall periods. Feasibility was fur-
ther judged by the percentage of missing values
per item and the percentage of missing items
per patient. In addition, the percentages of
multiple responses to items where only one
response was required were compared.
Reliability
The internal consistency was expressed in
Cronbach’s á coeYcients.23 An á coeYcient of
0.70 was considered suYcient. Because this
study was an intervention study, data on
test-retest reliability in stable subjects were not
available.
Validity
Two approaches were taken to assess the valid-
ity of the two questionnaires in this population.
Firstly, we examined cross sectional and longi-
tudinal construct validity by correlating the
quality of life scores with each other and with
symptom scores and lung function parameters.
To assess cross sectional construct validity we
correlated absolute scores and to assess longi-
tudinal construct validity we correlated change
scores. Conceptually similar domains should
be correlated stronger than domains which
have less in common. The strength of the cor-
relations was calculated using both Pearson’s
and Spearman’s correlation coeYcients. As no
major diVerences were found, Pearson’s corre-
lations are shown.
In the second approach, common factor
analysis with varimax rotation was employed to
examine the relationships between the ques-
tions of the two health status measures. Factors
were extracted using principal component
analyses and selected when their own value
(the variance explained by each factor) was
greater than 1.
Responsiveness
Responsiveness was assessed in three diVerent
ways. Firstly, the ability of the questionnaires to
detect within-subject changes was compared
by means of paired t tests. Secondly, we
compared the ability of the questionnaires to
detect diVerences in change between the treat-
ment groups. To test the hypothesis that the
mean quality of life scores of the three groups
after 12 weeks of treatment were equal, we used
analysis of covariance (ANCOVA) with treat-
ment group used as a factor and baseline score
used as a covariate. Only when the ANCOVA
indicated there were diVerences between the
group means adjusted for baseline score were
further ANCOVAs performed to determine
which group means were significantly diVerent
from each other. Thirdly, we compared the two
questionnaires with respect to the proportions
of patients in the three groups reaching the
minimally important improvement in quality of
life.
Results
PATIENTS
One hundred and forty four patients both
signed the informed consent form and met the
inclusion/exclusion criteria. Due to logistical
problems two of them did not complete the
quality of life questionnaire at baseline. Nine of
the remaining 142 patients failed to complete
the second quality of life measurement. Seven
patients dropped out because of an exacerba-
tion of COPD (four on placebo, two on
salmeterol/ipratropium bromide, and one on
salmeterol) and two patients because of an
adverse event (both on salmeterol). Hence, the
responsiveness of 133 patients was analysed.
Drop outs were compared with those who
remained in the study with regard to baseline
characteristics and quality of life and were not
found to be significantly diVerent. Table 1
shows that there were no statistically significant
diVerences between the three groups in base-
line characteristics including quality of life.
CLINICAL OUTCOMES
A description and discussion of the physiologi-
cal and clinical results will be published
elsewhere. To facilitate the interpretation of the
changes in quality of life it suYces to note here
that daytime symptom score, morning and
evening PEFR, FEV1, specific airway conduct-
ance (sGaw), and night-time use of rescue
drugs showed significantly more improvement
in patients receiving salmeterol or salmeterol
plus ipratropium bromide than in patients
receiving placebo. There were statistically
significant additional eVects of the combina-
tion treatment over and above salmeterol treat-
ment for evening PEFR and FEV1 % predicted.
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QUESTIONNAIRE CONTENT
Despite the labels, the symptoms domain of the
SGRQ and the dyspnoea domain of the CRQ
do not cover the same concept. The symptoms
domain refers to the frequency in which symp-
toms such as cough, shortness of breath, and
sputum production occur, while the dyspnoea
domain measures the extent to which certain
activities cause shortness of breath. Conceptu-
ally, the dyspnoea domain of the CRQ is more
closely related to the activity domain of the
SGRQ which asks about activities that cause
breathlessness and whether patients slow down
or rest while doing certain activities. The CRQ
has separate domains for fatigue and mastery,
the latter referring to disease control or coping.
The SGRQ contains a few questions about
fatigue and only one or two questions about
coping which are included in the impact
domain. The impact of the SGRQ domain fur-
ther assesses how the chest problems interfere
with social life, household activities, paid
employment, sports, etc. These items are not
addressed in the CRQ. The CRQ contains
more questions about emotions such as
frustrations, restlessness, embarrassment, wor-
ries, depression, and tension than the SGRQ.
FEASIBILITY
Whereas the response options of the CRQ
range from 1 to 7 for all questions, the response
options of the SGRQ frequently change from
5, 4 or 3 point Likert scales to true/false
response categories. The recall period of
SGRQ varied from “the last four weeks” for the
symptoms domain to “usually” or “these days”
for the other domains, whereas the recall
period of the CRQ remained four weeks for all
questions. As a result, patients indicated that
the SGRQ required more careful reading. Both
questionnaires contain few negatively worded
questions which use words such as “not”,
“rarely” or “never” and the length of the indi-
vidual questions was comparable.
Table 2 presents an overview of missing
values per question and per patient. Part 1 of
the SGRQ contains two questions—“How long
did the worst attack of chest trouble last?” (no.
6) and “If you have a wheeze, is it worse in the
morning?” (no. 8)—which frequently do not
apply to patients with COPD. As a result, the
answers to these questions were missing in
58% and 27% of the cases, respectively. In the
instruction manual of the SGRQ it is advised
that these questions be omitted from the score
calculation for patients who had not experi-
enced attacks or wheezing. If these questions
are not taken into account the number of miss-
ing values reduces considerably (table 2). Mul-
tiple responses to questions where a single
response was required were not observed in any
of the questionnaires.
Eliciting the patient’s five most important
activities is frequently reported as being the
most diYcult part of the CRQ. However, at
baseline all but two patients were able to recall
five activities that made them feel short of
breath. One patient recalled four activities and
one patient recalled only two activities. Of the
133 patients who completed the questionnaire
after 12 weeks of treatment only seven patients
changed one or more activities listed at
baseline. Since this is not allowed, these
responses were recoded to missing values.
RELIABILITY
The internal consistency of the CRQ was high
with á coeYcients ranging from 0.84 to 0.87.
The internal consistency of the SGRQ was
somewhat lower with á coeYcients ranging
from 0.76 to 0.77, but none of the á
coeYcients fell below 0.70 which is usually
considered good enough for group compari-
sons.
Table 1 Baseline characteristics by treatment group
Salmeterol+ ipratropium
bromide (n=47)
Salmeterol+
placebo (n=47)
Placebo+ placebo
(n=50) p value*
Age (years) 63.0 (7.1) 65.4 (5.8) 63.2 (7.4) 0.165
Years since onset of COPD 11.2 (10.0) 12.4 (10.7) 13.8 (11.0) 0.511
Sex (% male) 87.2% 89.4% 86.0% 0.880
Pre-bronchodilator FEV1 (l) 1.4 (0.4) 1.3 (0.4) 1.3 (0.4) 0.649
FEV1 (% predicted) 44.7 (11.3) 44.0 (9.6) 42.0 (10.8) 0.447
FVC (l) 3.1 (0.8) 2.9 (0.7) 3.0 (0.7) 0.432
PEFR (l/s) 279 (89) 267 (75) 264 (81) 0.624
Reversibility (% predicted) 6.7 (4.6) 5.7 (4.2) 5.8 (3.1) 0.385
Using inhaled steroids (%) 74 81 76 0.743
On salmeterol before start of the run in (%) 57 57 51 0.791
SGRQ:Total 48.3 (13.9) 50.5 (16.6) 50.2 (15.8) 0.640
Symptoms 54.0 (19.9) 52.7 (25.5) 54.4 (22.6) 0.936
Activities 64.0 (14.8) 65.7 (17.5) 64.5 (17.2) 0.879
Impact 37.2 (16.6) 42.2 (18.6) 40.9 (18.1) 0.387
CRQ: Total 4.44 (0.81) 4.58 (1.03) 4.22 (1.05) 0.241
Dyspnoea 3.21 (0.99) 3.64 (1.19) 3.45 (1.14) 0.331
Fatigue 4.35 (1.06) 4.33 (1.16) 4.11 (1.19) 0.553
Emotions 4.87 (1.00) 5.00 (1.10) 4.45 (1.28) 0.056
Mastery 5.31 (1.22) 5.26 (1.27) 4.92 (1.40) 0.278
Data are presented as mean (SD) unless otherwise stated.
FEV1 = forced expiratory volume in one second; FVC = forced vital capacity; PEFR = peak expiratory flow rate; SGRQ = St
George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Disease Questionnaire.
*ANOVA on means of three groups and ÷2 for proportions.
Table 2 Missing values
SGRQ CRQ
% of missing values per question (range) 0–58%
0–10%*
0–5.3%
% of missing values per patient 2.0%
0.25%*
0.54%
*When questions 6 and 8 of Part 1 are excluded.
SGRQ = St George’s Respiratory Questionnaire; CRQ =
Chronic Respiratory Disease Questionnaire.
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VALIDITY
Cross sectional construct validity
The cross sectional correlation matrix is shown
in table 3. The SGRQ activity and total score
correlated significantly with morning and
evening PEFR and the activity score correlated
significantly with FEV1 % predicted.
Nevertheless, the correlation between the
questionnaires and lung function measures was
weak. Both questionnaires correlated some-
what better with symptom scores. The total
scores of both questionnaires correlated best
with each other and with the domain scores.
The fatigue domain of the CRQ correlated well
with all domains of the SGRQ. Among the
domains of the SGRQ the impact domain cor-
related best with the other domains of the
CRQ, except dyspnoea. The weakest correla-
tion between the two questionnaires was that
between the dyspnoea domain of the CRQ and
the symptoms domain of the SGRQ.
Longitudinal construct validity
The longitudinal correlation matrix is shown in
table 4. Compared with the CRQ, the change
in SGRQ scores showed better correlation with
change in lung function. This applies especially
to the SGRQ activity score. Compared with the
cross sectional correlations, the longitudinal
correlations between the quality of life scores
and the symptom scores were worse. Again, the
SGRQ activity score correlated best. Like the
cross sectional correlations, the longitudinal
correlations were highest between the total
scores of the two questionnaires. The CRQ
fatigue domain correlated best with the SGRQ,
the CRQ dyspnoea domain correlated best
with the activity domain of the SGRQ, and the
CRQ mastery domain correlated best with the
SGRQ impact domain. Overall, the longitudi-
nal correlations between the two question-
naires were lower than the cross sectional cor-
relations.
Factor analysis
Based on the criterion of an eigenvalue of >1,
the factor analysis on the data of the CRQ
revealed three relatively independent factors,
explaining almost 65% of the total variance in
the original measure. The factor loadings after
varimax rotation are shown in table 5. No fac-
tor loading fell below 0.5. The first factor
extracted could be labelled “energy and
coping”. It showed positive correlation with
three of the four fatigue items, two of the four
mastery items, and three of the seven emotions
items. The second factor appears to reflect a
mental health dimension. It showed positive
correlation with four of the seven emotions
items and two of the four mastery items. The
third factor could be labelled “shortness of
breath” since it showed positive correlation
with all dyspnoea items and one fatigue item.
Factor analysis of the SGRQ data yielded 18
diVerent factors with an eigenvalue of >1,
explaining almost 73% of the variance. These
factors were very diYcult to interpret. When
the factor analysis was forced to extract three
Table 3 Cross section construct validity: Pearson’s correlation coeYcients
SGRQ CRQ
Symptoms Activity Impact Total Dyspnoea Fatigue Emotions Mastery Total
Symptoms
Daytime score 0.308** 0.194* 0.332** 0.344** −0.223** −0.324** −0.324** −0.297** −0.330**
Night-time score 0.138 0.299** 0.264** 0.296** −0.212* −0.330** −0.282** −0.171* −0.299**
Lung function
FEV1 (% pred) 0.004 −0.207* −0.124 −0.144 0.071 0.061 0.023 0.033 0.053
PEFR am −0.138 −0.252** −0.084 −0.169* 0.151 0.123 0.097 0.089 0.136
PEFR pm −0.172* −0.224** −0.094 −0.175* 0.124 0.109 0.086 0.085 0.120
SGRQ
Symptoms −0.352** −0.528** −0.518** −0.475** −0.562**
Activities −0.476** −0.577** −0.414** −0.365** −0.537**
Impact −0.367** −0.616** −0.633** −0.590** −0.664**
Total −0.469** −0.700** −0.645** −0.602** −0.725**
SGRQ = St George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Diseases Questionnaire; FEV1 = forced expiratory
volume in one second; PEFR = peak expiratory flow rate.
*p <0.05; **p <0.01.
Table 4 Longitudinal construct validity: Pearson’s correlation coeYcients
SGRQ CRQ
Symptoms Activity Impact Total Dyspnoea Fatigue Emotions Mastery Total
Symptoms
Daytime score 0.167 0.234** 0.056 0.186* −0.105 −0.133 −0.053 0.010 −0.083
Night-time
score
0.014 0.103 0.001 0.041 −0.076 −0.097 −0.124 −0.032 −0.105
Lung function
FEV1 −0.298* −0.332** +0.038 −0.195* 0.183* 0.258** 0.040 0.075 0.155
PEFR am −0.111 −0.256** −0.137 −0.224* 0.072 0.178* 0.050 0.080 0.107
PEFR pm −0.009 −0.203* −0.009 −0.126* 0.044 0.074 0.068 0.059 0.075
SGRQ
Symptoms −0.221* −0.457** −0.380** −0.346** −0.412**
Activities −0.338** −0.444** −0.324** −0.291** −0.414**
Impact −0.165 −0.303** −0.361** −0.379** −0.361**
Total −0.315** −0.528** −0.497** −0.486** −0.543**
SGRQ = St George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Diseases Questionnaire; FEV1 = forced expiratory
volume in one second; PEFR = peak expiratory flow rate.
*p <0.05; **p <0.01.
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factors only 28% of the variance was explained,
but the three factors were more closely related
to the original domains. The first factor showed
positive correlation with 10 of the 16 activity
items, 11 of the 26 impact items, and two of the
eight symptoms items. We labelled it “physical
activity” because many of the impact items
were asking about exercise. The second factor
showed positive correlation with seven of the
eight symptoms items, seven of the 26 impact
items (most of which were asking about cough-
ing or chest trouble), and four of the 16 activ-
ity items. The factor could therefore be labelled
“symptoms”. The third factor showed positive
correlation with eight impact items and one
activity item and was therefore labelled “im-
pact”. Twenty three items had a factor loading
below 0.4.When these items were excluded the
resemblance between the three factors and the
three original domains increased.
RESPONSIVENESS
The SGRQ symptom score and the CRQ
fatigue and total scores showed statistically sig-
nificant within-patient improvements in pa-
tients receiving salmeterol plus ipratropium
bromide. Except for a deterioration on the
CRQ emotions domain in the salmeterol
group, the other domains did not show statisti-
cally significant within-patient changes (table
6). Table 6 also shows that the changes in the
symptoms domain of the SGRQ and in the
total and emotions domains of the CRQ
diVered significantly between the three groups.
Further pairwise analyses revealed that the
symptoms score showed a significantly greater
improvement on treatment with salmeterol and
ipratropium bromide than on salmeterol alone
(mean diVerence 9.4; 95% CI 2.7 to 16.1) or
placebo (mean diVerence 8.7; 95% CI 1.3 to
16.2), neither of which showed a significant
change. The average diVerences exceeded the
minimally important diVerence of 4%. A
significantly greater improvement on combina-
tion treatment than on salmeterol treatment
was also found for the overall CRQ score
(mean diVerence 0.4; 95% CI 0.11 to 0.69)
and the CRQ emotions domain (mean diVer-
ence 0.51; 95% CI 0.17 to 0.83). These diVer-
ences were due to a worsening of scores with
salmeterol and an improvement of scores with
salmeterol plus ipratropium bromide. How-
ever, the changes on the CRQ remained below
what is considered the minimally clinically
important diVerence. Neither the SGRQ nor
the CRQ showed any significant diVerences
between salmeterol and placebo.
Table 5 Factor analysis with varimax rotation of CRQ
Loading
Percentage
of explained
variance
Factor 1 45.9
Worn out or sluggish (f) 0.785
Relaxed and free of tension (e) 0.765
Low in energy (f) 0.742
Happy, satisfied, pleased (e) 0.717
Discouraged or down in the dumps
(e)
0.714
Complete control of breathing
problems (m)
0.705
How much energy (f) 0.647
Confident and sure (m) 0.574
Factor 2 13.1
Fear or panic (m) 0.846
Upset or scared (m) 0.774
Frustrated or inpatient (e) 0.666
Embarrassed by coughing (e) 0.621
Restless, tense or uptight (e) 0.616
Upset, worried or depressed (e) 0.609
Factor 3 5.8
Item 4 (d) 0.794
Item 5 (d) 0.792
Item 3 (d) 0.786
Item 2 (d) 0.759
Item 1 (d) 0.712
How tired have you felt? (f) 0.571
d = dyspnoea; f = fatigue; e = emotions; m = mastery.
Table 6 Responsiveness to changes within subjects and diVerences in changes between
salmeterol + ipratropium bromide (n = 45), salmeterol + placebo (n = 43), and placebo +
placebo (n = 45)
Change in quality of life
p value†
(overall)
Salmeterol+
ipratropium
bromide
Salmeterol +
placebo
Placebo+
placebo
SGRQ –2.4 (11.0) –0.01 (7.1) +0.5 (9.2) 0.232
Symptoms –8.1 (15.3)** +1.4 (16.3) +0.7 (20.0) 0.019
Activities –2.6 (14.5) +0.5 (8.1) +1.2 (10.9) 0.227
Impact –0.5 (12.1) –0.5 (10.9) –0.1 (13.3) 0.944
CRQ 0.19 (0.6)* –0.21 (0.8) <0.01 (0.7) 0.036
Dyspnoea 0.21 (0.8) –0.08 (0.9) 0.07 (1.0) 0.368
Fatigue 0.25 (0.8)* –0.13 (0.9) <0.01 (0.9) 0.085
Emotions 0.17 (0.8) –0.34 (0.9)* 0.04 (0.8) 0.009
Mastery 0.17 (0.8) –0.20 (1.0) <0.01 (0.7) 0.130
SGRQ = St George’s Respiratory Questionnaire; CRQ = Chronic Respiratory Disease Question-
naire.
†Covariance analysis on change scores with treatment groups as a factor and baseline score as a
covariate. Improvement is indicated by a minus for the SGRQ and a plus for the CRQ.
Within-patient changes: *p<0.05; **p<0.001.
Figure 1 Percentage of patients showing a clinically
relevant change in quality of life according to (A) the
SGRQ (p = 0.743, Kruskal-Wallis test) and (B) the CRQ
(p = 0.005, Kruskal-Wallis test). The threshold for a
minimum clinically relevant change is 4 for the SGRQ and
0.5 for the CRQ. SLM = salmeterol; IB = ipratropium; PL
= placebo.
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Figure 1 shows the proportion of patients
reaching at least a minimum clinically relevant
change in the overall score of the two quality of
life questionnaires. Almost 40% of the patients
on combination treatment reached a clinically
relevant improvement in quality of life as
measured by the CRQ compared with 13% and
12% of the patients on salmeterol or placebo,
respectively. These proportions were signifi-
cantly diVerent. Of the patients on combination
treatment, 23% reached the minimally impor-
tant improvement on the SGRQ compared with
24% of the patients on salmeterol and 23% of
the patients on placebo. These proportions
were not significantly diVerent. Of all the
domain scores, the SGRQ symptoms and the
CRQ emotions domains showed a significantly
higher proportion of patients who reached a
clinically relevant improvement on combination
treatment (symptoms: 53% on salmeterol and
ipratropium bromide, 26% on salmeterol, 33%
on placebo; Kruskal-Wallis test, p = 0.024;
emotions: 32% on salmeterol and ipratropium
bromide, 9% on salmeterol, 22% on placebo;
Kruskal-Wallis test, p = 0.006).
Discussion
The results of this direct comparison of the
self-administered version of the CRQ and the
SGRQ in a clinical trial have confirmed their
feasibility for use in patients with moderate to
severe COPD. Completion rates were good for
both questionnaires, with that for the self-
administered version of the CRQ being even
better than the completion rate for the
interviewer-administered version of the CRQ
reported by Harper et al,14 probably because
our measurements were part of a clinical trial
whereas their measurements were done in rou-
tine clinical practice.
Although the internal consistency was some-
what better for the CRQ, both questionnaires
showed good internal consistency with á coef-
ficients above 0.75. We could not confirm the
findings of Wijkstra et al25 and Guell et al22 who
reported considerably lower internal consist-
ency values for the CRQ dyspnoea domain
than for the other CRQ domains of 0.53 and
0.51, respectively, compared with our value of
0.86. As all psychometric properties may
depend on patient characteristics, it is impor-
tant to point out that the studies by Wijkstra et
al and Guell et al were conducted in patients
with more severe illness than in our trial.
The validity of the two quality of life
questionnaires is supported by the correlations
between their total scores and their domain
scores. Almost all cross sectional and longitudi-
nal correlations are highly statistically signifi-
cant (p<0.01). Cross sectionally, the scores of
the two questionnaires were moderately to
highly correlated (coeYcients of 0.35–0.72).
The correlations between change scores were
lower, although the correlation between the
changes in total scores of the two question-
naires was still 0.54. The overall patterns of
correlations were consistent with expectations.
The CRQ domain fatigue correlated best with
the domains of the SGRQ.This fatigue domain
contains general items about tiredness and
energy which one would expect to be associ-
ated with symptoms, level of activity, and the
impact of the disease on daily life. The impact
domain of the SGRQ correlated best with the
emotions and mastery domains of the CRQ.
The impact domain of the SGRQ is a very
broad domain covering a wide variety of
concepts. Among the weakest correlations
found was the correlation between the dys-
pnoea domain of the CRQ and the symptoms
domain of the SGRQ. The CRQ dyspnoea
domain correlates best with the activity domain
of the SGRQ. This observation confirms our
qualitative comparison of domain content.
Despite the similarity of the domain labels, the
dyspnoea domain of the CRQ measures the
extent to which certain activities cause breath-
lessness, whereas the symptoms domain of the
SGRQ measures the frequency of symptom
occurrence.
When looking at the correlations with lung
function and symptom scores, the SGRQ
showed somewhat better validity than the
CRQ. Its correlation with change in lung func-
tion was better, as was its ability to discriminate
between patients with more or less severely
impaired lung function. Nevertheless, the cor-
relation between quality of life and lung
function and the ability of both questionnaires
to discriminate between patients with more or
less severely impaired lung function were
rather limited. This is not surprising given the
limited variation in lung function. Only pa-
tients with a pre-bronchodilator FEV1 between
40% and 65% were eligible. The small
variation in symptom scores might also explain
the relatively low longitudinal correlation
between quality of life and symptom scores.
Although we realise that it is diYcult to con-
firm factor structures in diVerent populations,
especially when the ratio of subjects to items is
not very large, we tried to compare the robust-
ness of the factor structure of the two
questionnaires. The factor analysis on data of
the CRQ proposed a three dimensional model
instead of the current four domains. In
particular, items of the mastery domain were
distributed over the first two factors. The con-
struction of the CRQ was not based on
psychometric approaches like factor analysis
but the items were selected using the “impact
method”.26 This method selects items that are
most frequently perceived as important by the
patients. The “impact method” and the
psychometric approach represent two diVerent
schools of thought. However, in reanalysing the
item pool generated for the construction of the
Asthma Quality of Life Questionnaire, Juniper
et al showed that the two methods generated
similar instruments.26 This was partly con-
firmed by our analysis of the CRQ. Little is
published about the item generation of the
SGRQ, but factor analysis did not seem very
suitable. It presupposed an 18-factor model
that could not be interpreted. When a three-
factor model was designed the proportion of
the variance that was explained by the model
fell from 73% to 28%.Almost 50% of the items
of the SGRQ had a factor loading below 0.4,
indicating a lack of homogeneity.
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Our study is one of the first clinical trials that
enables a direct comparison of the response of
the SGRQ and the CRQ to changes in health
resulting from bronchodilator therapy. The
symptoms domain was the most responsive of
the SGRQ. This domain not only showed a
statistically significant improvement of more
than 8% in patients receiving combination
treatment, but the improvement also exceeded
the 4% threshold for clinical relevance. In an
earlier study Jones and Lasserson found a
change of about 8% in patients who considered
their medication to be moderately eYcacious.17
Furthermore, the symptoms domain was the
only domain of the SGRQ which showed that a
significantly higher proportion of patients
reached a clinically relevant improvement on
combination treatment than on the other treat-
ments.
The total score of the CRQ and its fatigue
and emotions domains were also able to detect
changes in health. The total score and the
emotions domain showed that the changes in
health were statistically significantly diVerent
between the combination treatment and treat-
ment with salmeterol alone. Although the
changes in health were statistically significant,
they did not cross the threshold value of
minimally clinically important change.
Nevertheless, both the CRQ total and emo-
tions scores were able to show that a signifi-
cantly higher proportion of the patients receiv-
ing combination treatment reached a
minimally important improvement.
The minimally important diVerences of 0.5
for the CRQ and 4% for the SGRQ were
established by the designers of the question-
naires. Such diVerences may vary according to
type of patients, study setting, and
interventions.27 For the CRQ the minimally
important diVerence was established in pa-
tients with COPD undergoing inpatient reha-
bilitation treatment using two diVerent patient
oriented approaches, one within-patient and
one between-patient.21 For the SGRQ the
minimally important diVerence was also estab-
lished using two diVerent approaches, one
physician based2 and one patient based16 in
patients receiving nedocromil sodium. Little is
known about cross cultural diVerences in esti-
mates of the minimally important diVerence.
Dutch studies of the CRQ and SGRQ aimed at
confirming the values of minimally important
diVerence have not yet been conducted.
Because the ratio between the minimally
important diVerence and the standard devia-
tion of the scores is larger, the CRQ generally
requires a smaller sample size than the SGRQ
to detect the minimally important diVerence.
The power of this trial to detect a diVerence of
0.5 between two groups in the CRQ total score
was 89%, while the power to detect a 4%
diVerence in the SGRQ total score was 63%.
One of the limitations of this study is its rela-
tively short duration. A three month treatment
period might be too short for patients with
COPD to recognise fully the impact of an
eVective treatment. Improvement in breath-
lessness or exercise tolerance might not imme-
diately attract the patients’ attention because
they have adopted a life style in which they
avoid strenuous daily and leisure activities.
Another limitation is that we have selected
relatively stable patients, most of whom were
already well treated with bronchodilator and
anti-inflammatory medication. As a result,
most changes in quality of life were rather
small. More than 75% of the patients were
using inhaled corticosteroids before the start of
the trial. More than 50% of the patients were
already using salmeterol but they were required
to stop this during the two week run in period.
We believe that small improvements due to new
medications are typical for the current medical
practice with respect to COPD in The Nether-
lands where the condition of many patients is
already well controlled with existing medica-
tions. The small changes in health were not due
to ceiling eVects since the percentage of
patients with a baseline score above 80% of the
best possible score was only 1.4% on the
SGRQ and 10.9% on the CRQ. Hence, there
was enough room for improvement.
In conclusion, this analysis of psychometric
properties does not clearly favour one instru-
ment above the other. The completion rate of
the self-administered version of the CRQ was
good and comparable to the SGRQ. The inter-
nal consistency was somewhat better for the
CRQ but the longitudinal validity and dis-
criminative validity were somewhat better for
the SGRQ.The homogeneity of the domains of
the SGRQ can be improved. The symptoms
domain was the most responsive of the SGRQ
and the total and emotions scores were the
most responsive scores of the CRQ. Since the
psychometric performances of the CRQ and
the SGRQ are largely comparable, the choice
between these two instruments can be based on
other considerations such as the size of the
required sample which is smaller for the CRQ
than for the SGRQ, or the availability of refer-
ence values which favours the more widely
used SGRQ.
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